Novo launches $249 Wegovy subscription, undercutting Lilly as shares fall 30% [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk ( NYSE:NVO ) is stepping up its push to regain share in the obesity drug market, introducing a subscription-based pricing model that could improve access and pricing visibility for cash-paying patients. Starting Tuesday, patients can enroll in three-, six-, or 12-month plans through telehealth partners including Ro, Weight Watchers, and LifeMD, with the 12-month option pricing the Wegovy pen at $249 per monthabout $50 below Eli Lilly's ( NYSE:LLY ) lowest offering. Company representatives indicated the structure is designed to improve predictability for patients, particularly in a market where insurance coverage remains limited and a significant portion of users continue to pay out of pocket. Warning! GuruFocus has detected 2 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. The move comes as competitive pressure has been building. Novo's shares have declined as much as 1.4% in Copenhagen and are down roughly 30% this year,
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment [Yahoo! Finance]Yahoo! Finance
- PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment [TheStreet.com]TheStreet.com
- Wegovy Subscription Launched—Here’s How Much It Could Save Users A Year [Forbes]Forbes
- Popular Weight-Loss Drug Wegovy Unveils Subscription Service [MSNBC.com]MSNBC.com
- Novo Nordisk launches Wegovy subscription program [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website